Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat in Diffuse Cutaneous Systemic Sclerosis
NCT02283762Phase 2Completed
- Sponsor
- Bayer
- Start
- Jan 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial in diffuse cutaneous systemic sclerosis (dcSSc) comparing Riociguat with Placebo (2 arms). Primary endpoint: Modified Rodnan Skin Score at 52 weeks. Started Jan 2015; status: completed.
02
Drugs
riociguat
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NCT02283762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02283762.